In the phase 1b JAVELIN trial, pretreated patients with gastric/gastroesophageal junction cancers (GC/GEJ) responded well to avelumab, a PD-L1 antibody.
Please join with us to fuel the next wave of progress.
Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.
Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
